If youre struggling to choosebetweenGlaxoSmithKline (LSE: GSK)andShire (LSE: SHP), youre not alone.
Glaxo and Shire are two of the UKs premier pharmaceutical companies, with their individual strengths and weaknesses.
And choosing between the two is a tough task.
Lacklustre growth
Theres only one way to describe Glaxos growth: slow and steady.
Management expects2015 core earnings per shareto decline at a percentage rate in the high teens as sales of key drugs continue to fall.
However, new treatments will start to work their way through the companys treatment pipeline by 2016.
As sales of these new products begin to grow,management believes thatgroups revenue will grow at a low-to-mid single digit percentage per annum from 2016 to 2020. Core earnings per share are expected to expand at a rate in the mid-to-high single digits during the same period.
High income
As Ivementioned before, according to my figures, assuming a 7% per annum growth rate through to 2020, Glaxo is on track to earn 111p per share for full-year 2020.
This indicates that Glaxo is trading at a 2020 P/E of 13.2, which seems expensive for such lacklustre growth.
Still, Glaxos dividend yield makes up for the companys lack of growth. Based on current figures, Glaxo currently supports a dividend yield of 5.7% and the payout is covered 1.2 times by earnings per share. Management has stated that the companys dividend payout will be maintained at 80p per share for the next three years.
So overall, for income investors, Glaxo is a top pick, althoughgrowth investors will be left wanting more.
On the other hand, Shire is a top growth stock.
Accelerating growth
Over the past five years, Shires growth has exploded. Indeed, City analysts expect the company to report earnings per share of 247p for 2015, 250% higher than the figure reported for 2010.
But the company is not content with this impressive organic growth rate. Management is on the hunt for acquisitions to boost growth and it has been reported thatShire recently made a 12bn bid for its peer, Actelion of Switzerland.
According to news reports,Actelion which makes treatments for rare diseases has rejected Shires initial approaches. However, theres nothing to stop Shire coming back and making another offer.
Shire has already completed one acquisition this year, a $5.2bn deal forNPS Pharmaceuticals. NPSspecialises in treatments for rare diseases and one has one drug approval for sale at present.
Costly shares
Excluding extraordinary items, Shires earnings per share are set to expand by a high double-digit percentage this year. Further growth of 17%is expectedduring 2016.
Unfortunately, this means that the market has placed a high valuation on the companys shares.
Shire is currently trading at a forward P/E of 21.9 and a 2016 P/E of 18.9. However, the companys dividend yield leaves a lot to be desired.
Shire offers a token yield of 0.3%, although the payout is covered 24x by earnings per share. According to analysts, Shires payout is set to grow by 50% during the next two years as Shire returns more cash to investors.
Its up to you
Overall, Shire and Glaxo are two different companies for two different types of investors. Shire is a growth stock, with its best days ahead of it. Glaxo has become the perfect stock for income investors, although the companys glacial growth rate leaves much to be desired.
But if neither Shire nor Glaxoappeals to you, then The Motley Fool’s top analysts have recentlyidentified a biotechwhose near-term potential upside, they reckon, could be as high as 45%!
All is revealed inour new free reportentitled“Is This Stock Tomorrow’s Big Winner?”The company in question has a substantial cash balance, provenadvantageand is supported by some of the industry’s biggest players!
If you’d like to find out more, download thefree report today— but hurry, it’s onlyavailable for a limited time.
Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
